









































Pharmaceuticals – Pipeline Übersicht¹ (Stand 26. April, 2023)

Phase 0 ²	Phase I	Phase II	Phase III
DGKalpha-Inh (BAY 2862789)  ●	Elimusertib (ATR-Inhibitor) (BAY 1895344)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Copanlisib (PI3K-Inhibitor)  ○
PSMA TAC (BAY 3546828)  ●	AhR-Inhibitor (BAY 2416964)  ●	Asundexian (FXIa-Inhibitor) (BAY 2433334)  ●	Darolutamide (AR-Inhibitor)  ○
PSMA SMOL TAC (BAY 3563254)  ●	mEGFR-Inhibitor (BAY 2927088)  ●	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)  ●	Finerenone (MR-Antagonist)  ○
VVD Keap1-Akt (BAY 3605349)  ●	DGKzeta-Inhibitor (BAY 2965501)  ●	Zabedoseritib (IRAK4-Inh.) (BAY 1834845)  ●	Vericiguat (sGC-Stimulator)  ○
VVD STAT3-Inh (BAY 3630914)  ●	CCR8 Ab (BAY 3375968)  ●	Gadoquatrane (Kontrastmittel Hoher Relaxivität) (BAY 1747846)  ●	Asundexian (FXIa-Inhibitor)  ●
SEMA 3a (BAY 3401016)  ●	Herzinsuffizienz rAAV Gentherapie (AB-1002 aka NAN-101)  ●	Runcaciguat (sGC-Aktivator) (BAY 1101042)  ●	Elinzanetant (Neurokinin-1,3 Rez.-Antagonist)  ●
Anti-Koagulant (BAY 3389934)  ●	sGC-Aktivator Oral (BAY 3283142)  ●		
Nächste Generation Leber-MRT (BAY 3393081)  ●	Anti-a2AP (BAY 3018250)  ●		
	sGC Aktivator Inhale (BAY 1211163)  ●		
	Bemdaneprocel (Morbus Parkinson-Zelltherapie) (BRT-DA01)  ●		
	Morbus Parkinson rAAV Gentherapie (AB-1005 aka AAV2-GDNF-PD)  ●		
	Multiple Systematrophie rAAV Gentherapie (AB-1005 aka AAV2-GDNF-MSA)  ●		
	Morbus Pompe rAAV Gentherapie (ACTUS-101)  ●		
	Huntington-Krankheit rAAV Gentherapie (AB-1001 aka BV-101)  ●		
	LGMD2I/R9 rAAV Gentherapie (AB-1003 aka LION-101)  ●		
	GPR84-Antagonist (BAY 3178275)  ●		

Einreichungen
Aflibercept 8MG  ○
// EU, JP, US ⁴ : Diabetisches Makulaödem (DME)
// EU, JP, US ⁴ : Neovasc. Altersbed. Makuladegeneration (nAMD)

-  Onkologie
-  Herz-Kreislauf*
-  Neurologie & Seltene Erkrankungen
-  Immunologie & Entzündungen
-  Andere

- Neue aktive Substanz
- Life cycle management

* Einschließlich Präzisions-Herz-Kreislauftherapien, Nephrologie & Akutversorgung

¹ Bayer und Partner gesponsorte Studien, sowie zulassungsrelevante Studien Dritter mit erstem Studienbesuch des ersten Patienten (m/w/d) ² Präklinische ausgewählte Programme auf dem Weg zur IND-Zulassung (Investigational New Drug Application, USA) ³ Durchgeführt von Merck & Co ⁴ US Einreichung durch Regeneron

